Report : North America Cerebrospinal Fluid Management Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Neurological Centers)
The CSF shunts segment by product is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America Cerebrospinal Fluid Management Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, End User and Country.” The North America cerebrospinal fluid management market is expected to reach US$ 1,060.40 million by 2028 from US$ 760.52 million in 2021; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028. The report highlights trends prevailing in the North America cerebrospinal fluid management market and the factors driving market along with those that act as hindrances.
Brain and spinal injuries are the most common causes of cerebrospinal fluid (CSF) leak in adults, necessitating CSF management. According to the Journal of Neurosurgery, more than 69 million people globally are expected to suffer from traumatic brain injuries annually. Therefore, it is expected that brain and spinal injuries are among the major driving factors for CSF management.
Other leading factor for the CSF leak among adults and elders is high blood pressure, which is majorly caused due to shift in lifestyle and unhealthy habits. Similarly, the increasing number of older people leads to rising incidences of high blood, which ultimately leads to an increasing risk of idiopathic intracranial hypertension (IIH).
On the other hand, the incidences of hydrocephalus are growing significantly across the world. Also, the data published by the Hydrocephalus Association states that in the United States, 1 in every 770 babies develops hydrocephalus, and over 1 million people live with hydrocephalus in the country. Therefore, considering the aforementioned factors, the demand for CSF management market is likely to grow significantly in the coming future. Growing advancements in the field of medical devices have led to extraordinary developments and innovations. The growing demand for better treatments has resulted in various product developments, resulting in market growth. For instance, in January 2020, Biocept initiated the commercial launch of CSF assay and CNSide. CNSide assists in identifying and managing the treatment of metastatic cancers that involves the central nervous system. Furthermore, CNSide is designed for quantitative tumor cell capture and detection method, and these analyses are paired with assays to identify molecular treatment targets.
North America has been adversely affected by the COVID-19 pandemic. However, the situation varies from one country to another across the region. COVID-19 outbreak posed problems for health systems across the US in 2020. However, recent spikes in cases and hospitalizations suggest that pressure will become widespread in the coming months, with less resiliency across the country to support surges in care demand. To manage demand early in the pandemic, some clinicians relied on resources from other parts of the country, such as supplies, and postponed "elective" care to free up resources for COVID-19 patients.
The impact of the COVID-19 pandemic on people suffering from neurological disorders and the whole American health system is the topic of this year's special segment. Reduced resources and decreased availability to care, as a result of the pandemic are expected to make surgeries and treatment difficult, resulting in lower incidence, higher mortality, and lower survival in the future. This has raised fears that COVID-19 problems and mortality may be common in patients affected by neurological disorders. Geriatric population, hydrocephalus, hypertension, cardiovascular disease, and diabetes have all been consistently related to an elevated risk of severe disease and/or death in patients.
The North America cerebrospinal fluid management market, by product, is segmented into CSF shunts and CSF drainage systems. In 2021, the CSF shunts segment held a larger share of the market. The North America cerebrospinal fluid management market, by end user, is segmented into hospitals, clinics, ambulatory surgical centers, and neurological centers. Geographically, the North America cerebrospinal fluid management market is sub-segmented into U.S, Canada and Mexico.
Medtronic, Integra Life Sciences Corporation, B. Braun Melsungen AG, DePuy Synthes, Sophysa, BeckerSmith Medical, Möller Medical GmbH, Natus Medical Incorporated and Spiegelberg GmbH & Co. KG are among the leading companies operating in the North America cerebrospinal fluid management market.
Contact Person: Sameer Joshi
Email Id: email@example.com